Subunit Vaccine Consisting of Multi-Stage Antigens Has High Protective Efficacy against Mycobacterium tuberculosis Infection in Mice

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Xin, Qi ^a   Niu, Hongxia ^a   Li, Zhi ^a   Zhang, Guoping ^a   Hu, Lina ^b   Wang, Bingxiang ^b   Li, Jingjing ^a   Yu, Hongjuan ^a   Liu, Wanbo ^a   Wang, Yue ^a   Da, Zejiao ^a   Li, Ruiying ^a   Xian, Qiaoyang ^c   Wang, Yong ^c   Zhang, Ying ^d   Jing, Tao ^a   Ma, Xingming ^a   Zhu, Bingdong ^a  

^a LANZHOU UNIVERSITY   (China)

^b LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS   (China)

^c WUHAN UNIVERSITY   (China)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; AG85B PROTEIN; BCG VACCINE; CORD FACTOR; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; ESAT6 PROTEIN; GELATIN; HSPX PROTEIN; HYBRID PROTEIN; MTB10 PROTEIN; MTB8 PROTEIN; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM VACCINE; POLYCYTIDYLIC ACID; RPFE PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL REPRODUCTION; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; EMULSION; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; LIFE CYCLE STAGE; LUNG; MOUSE; NONHUMAN; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN SYNTHESIS; SPLEEN; TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BCG VACCINE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MICE; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT FUSION PROTEINS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT;

EID: 84881568384     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072745     Document Type: Article

References (49)

1. Andersen P, (2007) Vaccine strategies against latent tuberculosis infection. Trends Microbiol 15: 7-13. doi:10.1016/j.tim.2006.11.008. PubMed: 17141504.
2. Zhang Y, (2008) Immunopathogenesis of tuberculosis: Implications for vaccine development. Respirology 13: S81-S87. doi:10.1111/j.1440-1843.2008.01350.x.
3. Kochi A, (1991) The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 79: 71-75. PubMed: 1882440.
4. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, et al. (2009) Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373: 1861-1873. doi:10.1016/S0140-6736(09)60331-7. PubMed: 19375159.
5. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, et al. (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368: 1575-1580. doi:10.1016/S0140-6736(06)69573-1. PubMed: 17084757.
6. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, et al. (2007) Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 13: 380-387. doi:10.3201/eid1303.061400. PubMed: 17552090.
7. Ghebreyesus TA, Kazatchkine M, Sidibé M, Nakatani H, (2010) Tuberculosis and HIV: time for an intensified response. Lancet 375: 1757-1758. doi:10.1016/S0140-6736(10)60595-8. PubMed: 20488527.
8. Harries AD, Zachariah R, Corbett EL, Lawn SD, Santos-Filho ET, et al. (2010) The HIV-associated tuberculosis epidemic-when will we act? Lancet 375: 1906-1919. doi:10.1016/S0140-6736(10)60409-6. PubMed: 20488516.
9. Calmette A, (1931) Preventive Vaccination Against Tuberculosis with BCG. Proc R Soc Med 24: 1481-1490. PubMed: 19988326.
10. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, et al. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271: 698-702. doi:10.1001/jama.1994.03510330076038. PubMed: 8309034.
11. Trunz BB, Fine P, Dye C, (2006) Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367: 1173-1180. doi:10.1016/S0140-6736(06)68507-3. PubMed: 16616560.
12. Fine PE, (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 1339-1345. doi:10.1016/S0140-6736(95)92348-9. PubMed: 7475776.
13. Kaufmann SH, Gengenbacher M, (2012) Recombinant live vaccine candidates against tuberculosis. Curr Opin Biotechnol 23: 900-907. doi:10.1016/j.copbio.2012.03.007. PubMed: 22483201.
14. Cardona PJ, Amat I, Gordillo S, Arcos V, Guirado E, et al. (2005) Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 23: 1393-1398. doi:10.1016/j.vaccine.2004.09.008. PubMed: 15661388.
15. Sweeney KA, Dao DN, Goldberg MF, Hsu T, Venkataswamy MM, et al. (2011) A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 17: 1261-1268. doi:10.1038/nm.2420. PubMed: 21892180.
16. Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, et al. (2008) Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 198: 544-552. doi:10.1086/590185. PubMed: 18582195.
17. Xing Z, McFarland CT, Sallenave JM, Izzo A, Wang J, et al. (2009) Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLOS ONE 4: e5856. doi:10.1371/journal.pone.0005856. PubMed: 19516906.
18. von Reyn CF, Mtei L, Arbeit RD, Waddell R, Cole B, et al. (2010) Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24: 675-685. doi:10.1097/QAD.0b013e3283350f1b. PubMed: 20118767.
19. Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, et al. (1996) Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 2: 893-898. doi:10.1038/nm0896-893. PubMed: 8705859.
20. Brandt L, Skeiky YA, Alderson MR, Lobet Y, Dalemans W, et al. (2004) The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 72: 6622-6632. doi:10.1128/IAI.72.11.6622-6632.2004. PubMed: 15501795.
21. Aeras, (2012) Vaccine development process. Available: http://www. aeras.org.
22. Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, et al. (2011) A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 17: 189-194. doi:10.1038/nm.2285. PubMed: 21258338.
23. Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, et al. (2010) A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2: 53ra74.
24. Zhang Y, (2007) Advances in the treatment of tuberculosis. Clin Pharmacol Ther 82: 595-600. doi:10.1038/sj.clpt.6100362. PubMed: 17898708.
25. Cohen-Gonsaud M, Keep NH, Davies AP, Ward J, Henderson B, et al. (2004) Resuscitation-promoting factors possess a lysozyme-like domain. Trends Biochem Sci 29: 7-10. doi:10.1016/j.tibs.2003.10.009. PubMed: 14729326.
26. Kana BD, [!(surname)!], Downing KJ, Sung N, Vostroktunova G, Machowski EE, Tsenova L, Young M, Kaprelyants A, Kaplan G, Mizrahi V, (2007) The resuscitation-promoting factors of Mycobacterium tuberculosis are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitro. Mol Microbiol. 67: 672-684. PubMed: 18186793.
27. Downing KJ, Mischenko VV, Shleeva MO, Young DI, Young M, et al. (2005) Mutants of Mycobacterium tuberculosis lacking three of the five rpf-like genes are defective for growth in vivo and for resuscitation in vitro. Infect Immun 73: 3038-3043. doi:10.1128/IAI.73.5.3038-3043.2005. PubMed: 15845511.
28. Skjøt RL, Oettinger T, Rosenkrands I, Ravn P, Brock I, et al. (2000) Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun 68: 214-220. doi:10.1128/IAI.68.1.214-220.2000. PubMed: 10603390.
29. Coler RN, Skeiky YA, Vedvick T, Bement T, Ovendale P, et al. (1998) Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of Mycobacterium tuberculosis. J Immunol 161: 2356-2364. PubMed: 9725231.
30. Ulrichs T, Munk ME, Mollenkopf H, Behr-Perst S, Colangeli R, et al. (1998) Differential T cell responses to Mycobacterium tuberculosis ESAT6 in tuberculosis patients and healthy donors. Eur J Immunol 28: 3949-3958. doi:10.1002/(SICI)1521-4141(199812)28:12. PubMed: 9862331.
31. Silver RF, Wallis RS, Ellner JJ, (1995) Mapping of T cell epitopes of the 30-kDa alpha antigen of Mycobacterium bovis strain bacillus Calmette-Guerin in purified protein derivative (PPD)-positive individuals. J Immunol 154: 4665-4674. PubMed: 7722319.
32. Lozes E, Huygen K, Content J, Denis O, Montgomery DL, et al. (1997) Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine 15: 830-833. doi:10.1016/S0264-410X(96)00274-5. PubMed: 9234526.
33. Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, et al. (2005) Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 174: 6332-6339. PubMed: 15879133.
34. Horwitz MA, Lee BW, Dillon BJ, Harth G, (1995) Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 92: 1530-1534. doi:10.1073/pnas.92.5.1530. PubMed: 7878014.
35. Niu H, Hu L, Li Q, Da Z, Wang B, et al. (2011) Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX. Vaccine 29: 9451-9458. doi:10.1016/j.vaccine.2011.10.032. PubMed: 22024175.
36. Luo Y, Wang B, Hu L, Yu H, Da Z, et al. (2009) Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice. Vaccine 27: 6179-6185. doi:10.1016/j.vaccine.2009.08.018. PubMed: 19712772.
37. Zhu B, Xin Q, Hu L, Wang B, Da Z, et al. (2011) Mycobacterium tuberculosis fusion protein and its preparation method and use thereof. International Application No. PCT/CN2011/001071.
38. Zhu B, Niu H, Hu L, Li Q, Wang B, et al. (2010) The construction method of a novel Mycobacterium tuberculosis fusion protein Mtb10.4-Hsp16.3 and its application. China Patent 201010613320.6.
39. Pym AS, Brodin P, Brosch R, Huerre M, Cole ST, (2002) Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol 46: 709-717. doi:10.1046/j.1365-2958.2002.03237.x. PubMed: 12410828.
40. van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, Lingnau K, Nouta J, Klein MR, Rosenkrands I, Ottenhoff TH, Kromann I, Doherty TM, Andersen PJT, vD, SM A, C P, P B, PN T,et al (2010) Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine 28: 3571-3581. doi:10.1016/j.vaccine.2010.02.094. PubMed: 20226890.
41. Li Q, Yu H, Zhang Y, Wang B, Jiang W, et al. (2011) Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice. Scand J Immunol 73: 568-576. doi:10.1111/j.1365-3083.2011.02531.x. PubMed: 21323695.
42. Wang CC, Zhu B, Fan X, Gicquel B, Zhang Y, (2013) Systems approach to tuberculosis vaccine development. Respirology 18: 412-420. doi:10.1111/resp.12052. PubMed: 23331331.
43. Pollock JM, Pollock DA, Campbell DG, Girvin RM, Crockard AD, et al. (1996) Dynamic changes in circulating and antigen-responsive T-cell subpopulations post-Mycobacterium bovis infection in cattle. Immunology 87: 236-241. doi:10.1046/j.1365-2567.1996.457538.x. PubMed: 8698385.
44. Welsh MD, Cunningham RT, Corbett DM, Girvin RM, McNair J, et al. (2005) Influence of pathological progression on the balance between cellular and humoral immune responses in bovine tuberculosis. Immunology 114: 101-111. doi:10.1111/j.1365-2567.2004.02003.x. PubMed: 15606800.
45. Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, et al. (1998) Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280: 1432-1435. doi:10.1126/science.280.5368.1432. PubMed: 9603732.
46. Korn T, Bettelli E, Oukka M, Kuchroo VK, (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27: 485-517. doi:10.1146/annurev.immunol.021908.132710. PubMed: 19132915.
47. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369-377. doi:10.1038/nrm2146. PubMed: 17351619.
48. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, et al. (1996) T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 183: 2593-2603. doi:10.1084/jem.183.6.2593. PubMed: 8676080.
49. Li Q, Li J, Tian J, Zhu B, Zhang Y, et al. (2012) IL-17 and IFN-gamma production in peripheral blood following BCG vaccination and Mycobacterium tuberculosis infection in human. Eur Rev Med Pharmacol Sci 16: 2029-2036. PubMed: 23242733.